Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
Cancer Medicine,
Journal Year:
2025,
Volume and Issue:
14(4)
Published: Feb. 1, 2025
ABSTRACT
Background
Recently,
a
plethora
of
novel
systemic
agents
have
been
incorporated
into
the
therapeutic
armamentarium
advanced
urothelial
carcinoma
(aUC).
The
antibody–drug
conjugate
(ADC),
enfortumab
vedotin
(EV),
has
demonstrated
relevant
clinical
benefit
in
patients
with
aUC
refractory
to
platinum
and
immune‐checkpoint
inhibitor
(ICI)
therapy.
Our
study
provides
retrospective,
international,
real‐world
analysis
comparing
effectiveness
EV
chemotherapy
this
setting.
Methods
data
were
extracted
from
medical
records
treated
or
following
pembrolizumab
for
recurrent
progressive
after
platinum‐based
chemotherapy.
Patients
assessed
overall
survival
(OS),
progression‐free
(PFS),
response
rate
(ORR)
duration
(DoR).
Results
included
247
(88,
36%)
(159,
64%).
Median
OS
was
9.1
months
(95%CI
7.2–10.7)
population,
13.6
10.0–31.0)
receiving
6.8
6.0–8.9)
(
p
<
0.001).
not
affected
by
primary
tumour
site
histology,
metastatic
sites,
type
first
pembrolizumab.
In
cohort,
median
PFS
significantly
longer
(8.8
[95%CI
6.5–17.0]
vs.
3.0
2.6–3.7])
ORR
higher
(56%
23%)
than
cohort.
Conclusions
results
our
international
confirm
sequential
strategy
who
received
prior
anti‐PD‐1
pembrolizumab,
regardless
commonly
considered
prognostic
factors.
Trial
Registration:
ClinicalTrials.gov
identifier:
NCT05290038
Language: Английский
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
Mohammad Javad Khosravanian,
No information about this author
Yousef Mirzaei,
No information about this author
Ali Hussein Mer
No information about this author
et al.
Life Sciences,
Journal Year:
2024,
Volume and Issue:
352, P. 122910 - 122910
Published: Sept. 1, 2024
Language: Английский
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior AvelumabVersusPembrolizumab Therapy
Anticancer Research,
Journal Year:
2024,
Volume and Issue:
44(8), P. 3419 - 3426
Published: July 26, 2024
Background/Aim:
This
study
retrospectively
evaluated
whether
enfortumab
vedotin
(EV)
monotherapy
is
effective
as
a
late-line
treatment
according
to
prior
type
in
patients
with
advanced
urothelial
carcinoma
(UC).
Patients
and
Methods:
We
assessed
consecutive
from
the
Uro-Oncology
Group
Kyushu
population
lower
upper
urinary
tract
cancer
treated
EV
after
platinum-based
chemotherapy
immune
checkpoint
inhibitor
therapy
failure
between
December
2021
March
2024.
In
particular,
receiving
avelumab
maintenance
or
pembrolizumab
before
for
UC
were
analyzed
compared
response
rate,
progression-free
survival
(PFS),
overall
(OS).
Results:
Of
80
enrolled
patients,
31
49
received
therapy,
respectively.
The
groups
had
comparable
objective
rates
(48.4%
vs.
44.9%,
p=0.820)
disease
control
(77.4%
67.3%,
p=0.448).
These
two
showed
no
significant
difference
PFS
initiation
of
(median:
6.4
months
4.2
months,
p=0.184);
meanwhile,
group
better
OS
than
16.0
10.2
p=0.019).
Moreover,
median
first-line
was
longer
(40.3
24.7
p=0.054).
On
multivariate
analysis,
reduced
mortality
risk
by
47%
(95%
confidence
interval=0.27-1.03;
p=0.059).
Conclusion:
provides
favorable
outcomes
UC.
Language: Английский
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives
Current Opinion in Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
Rare
cancers
of
the
genitourinary
(GU)
tract
are
often
clinically
aggressive
yet
have
few
or
no
standard-of-care
treatments.
Multiple
antibody-drug
conjugates
(ADCs)
been
approved
in
solid
malignancies.
This
review
explores
use
ADCs
rare
GU
tumors
context
biological
pathways
and
ongoing
research
tumors.
Few
clinical
trials
focus
on
recruiting
participants
with
tract,
including
testing
enfortumab
vedotin
as
monotherapy
combined
pembrolizumab,
sacituzumab
govitecan
atezolizumab.
We
highlight
many
novel
for
advanced/metastatic
emphasize
potential
eligibility
patients
tumor-agnostic
trials.
being
tested
multiple
tumors,
Ongoing
preclinical
supports
some
several
improves
our
understanding
their
pathophysiology.
Language: Английский
Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer
American Society of Clinical Oncology Educational Book,
Journal Year:
2024,
Volume and Issue:
44(3)
Published: June 1, 2024
Urothelial
cancer
(UC)
is
the
most
common
histology
seen
in
bladder
tumors.
The
2022
WHO
classification
of
urinary
tract
tumors
includes
a
list
less
subtypes
(formerly
known
as
variants)
for
invasive
UC
which
are
considered
high-grade
This
review
summarizes
recent
advances
management
selected
nonurothelial
cancer:
squamous
cell
carcinoma,
small
sarcomatoid
urothelial
micropapillary
plasmacytoid
adenocarcinoma,
and
urachal
carcinoma.
role
neoadjuvant
adjuvant
chemotherapy
has
not
been
well
characterized
these
histologies,
prospective
data
extremely
limited.
Participation
clinical
trials
recommended
advanced
disease.
Language: Английский
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Yujiro Nagata,
No information about this author
Akinori Minato,
No information about this author
Hisami Aono
No information about this author
et al.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(19), P. 10348 - 10348
Published: Sept. 26, 2024
Locally
advanced
or
metastatic
urothelial
carcinoma
is
a
genomically
and
molecularly
heterogeneous
disease
associated
with
various
clinical
outcomes.
We
aimed
to
evaluate
the
association
between
status
of
p53/FGFR3
expression
efficacy
enfortumab
vedotin
(EV)
in
carcinoma.
evaluated
p53
(abnormal
vs.
wild-type)
FGFR3
(high
low)
determined
by
immunohistochemistry
response
EV
28
patients
Overall,
60.7%
showed
abnormal
p53,
17.9%
had
high
expression.
The
rates
objective
were
statistically
higher
than
those
wild-type
(p
=
0.038).
Patients
pure
(n
18)
low
significantly
better
FGFR3.
When
statuses
combined,
p53/low
(vs.
p53/high
FGFR3)
was
strongly
favorable
outcomes
both
entire
cohort
0.002)
cases
only
0.023).
Immunohistochemically
tumors
found
respond
well
EV,
while
poorer
response.
Thus,
are
potential
biomarkers
for
predicting
treatment
Language: Английский
Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan
Keita Nakane,
No information about this author
Kazuki Taniguchi,
No information about this author
Minori Nezasa
No information about this author
et al.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(15), P. 2648 - 2648
Published: July 25, 2024
Randomized
phase
III
trial
results
have
demonstrated
enfortumab
vedotin
(EV),
an
antibody–drug
conjugate
(ADC)
consisting
of
anti-Nectin-4
human
IgG1
monoclonal
antibody
and
monomethyl
auristatin
E,
is
a
useful
treatment
for
patients
with
locally
advanced
or
metastatic
urothelial
carcinoma
(la/mUC)
that
progressed
after
immune
checkpoint
inhibitor
(ICI)
therapies.
This
multicenter
retrospective
cohort
study
aimed
to
identify
predictive
factors
the
efficacy
EV
therapy
prolonged
overall
survival
(OS)
in
clinical
practice.
included
la/mUC
who
received
ICI
treatment.
Patients
subsequently
treatment,
those
non-EV
chemotherapy,
no
were
defined
as
EV,
non-EV,
best
supportive
care
(BSC)
groups,
respectively.
The
median
OS
was
20,
15,
7
months
BSC
respectively
(p
<
0.001).
had
complete
partial
response
significantly
compared
stable
progressive
disease.
Univariate
analysis
showed
age,
neutrophil-to-lymphocyte
ratio
(NLR),
dysgeusia,
rash
independent
predictors
improvement.
NLR
dysgeusia
multivariate
analysis.
without
these
both
factors.
In
real-world
practice,
effective
Language: Английский
Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer
Japanese Journal of Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 22, 2024
Abstract
Objective
This
study
aimed
to
assess
the
oncological
outcomes
of
subtype
urothelial
carcinoma
(SUC),
including
divergent
differentiation
and
histologic
subtype,
in
comparison
with
those
pure
(PUC)
nonmuscle-invasive
bladder
cancer.
Methods
We
retrospectively
evaluated
patients
who
were
initially
treated
transurethral
resection
tumor
(TURBT)
between
March
2005
August
2020
at
a
single
institution.
Patients
PUC
SUC
compared
terms
recurrence-free
survival
(RFS),
progression-free
(PFS),
overall
(OS).
Results
Out
853
enrolled
patients,
783
(91.8%)
70
(8.2%)
had
SUC,
respectively.
presence
was
significantly
associated
old
age,
size
(≥3
cm),
higher
pT1
rate,
high
grade,
concomitant
situ,
lymphovascular
invasion.
RFS
rates
after
TURBT
did
not
differ
groups.
With
median
follow-up
period
66
months
(interquartile
range,
38–103
months),
time
progression
muscle
invasion
6.9%
22.5
group,
22.9%
10.0
group.
Moreover,
incidence
metastasis
4.6%
15.7%
groups,
The
5-year
PFS
(64.5%
81.9%,
P
<
.001)
OS
(71.7%
86.2%,
=
.009)
lower
group
than
On
multivariate
analysis,
independently
predicted
metastasis.
Conclusion
At
initial
diagnosis,
we
must
pay
more
attention
risk
that
Language: Английский
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu
Translational Andrology and Urology,
Journal Year:
2024,
Volume and Issue:
13(7), P. 1118 - 1126
Published: July 1, 2024
Background:
The
subtype
of
urothelial
carcinoma
(SUC)
has
been
known
to
possess
morphological
diversity
for
histologic
or
divergent
differentiation.
However,
the
efficacy
avelumab
against
SUC
remains
unclear.
Therefore,
effect
treatment
as
well
survival
results
monotherapy
were
evaluated
a
first-line
therapeutic
maintenance
in
patients
with
advanced
SUC.
Methods:
A
retrospective
analysis
was
conducted
on
consecutive
from
Uro-Oncology
Group
Kyushu
study
population
lower
and
upper
urinary
tract
cancer
who
underwent
therapy
without
progression
after
platinum-based
chemotherapy.
Patients
pure
(PUC)
comparatively
analyzed
based
objective
response
rate
(ORR),
disease
control
rate,
progression-free
(PFS),
overall
(OS).
Results:
Out
49
recorded
patients,
38
11
had
PUC
SUC,
respectively.
most
common
element
glandular
differentiation
(n=5),
followed
by
squamous
(n=3),
micropapillary
(n=1),
plasmacytoid
subtypes
(n=1).
groups
comparable
ORR
(0%
vs.
2.6%,
P>0.99)
rates
(54.5%
44.7%,
P=0.73).
These
patient
also
showed
no
significant
difference
PFS
(median
3.9
3.1
months,
P=0.33)
OS
16.7
22.1
P=0.47).
Conclusions:
cancer,
indicating
that
is
effective
Language: Английский